Published in Health Insurance Law Weekly, October 17th, 2004
There has also been a conscious move in developed societies to increase the use of generic and biogeneric products for containing healthcare expenses.
New analysis from Frost & Sullivan, "World Generics and Biogenerics Markets," reveals the global generics and biogenerics markets revenue totaled $35.4 billion in 2003 and is projected to reach $71.9 billion in 2010.
In the United States, health plan providers are offering incentives for plan members to use generic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.